key: cord-0948577-jzfr2t3p
authors: Mudatsir, Mudatsir; Fajar, Jonny Karunia; Wulandari, Laksmi; Soegiarto, Gatot; Ilmawan, Muhammad; Purnamasari, Yeni; Mahdi, Bagus Aulia; Jayanto, Galih Dwi; Suhendra, Suhendra; Setianingsih, Yennie Ayu; Hamdani, Romi; Suseno, Daniel Alexander; Agustina, Kartika; Naim, Hamdan Yuwafi; Muchlas, Muchamad; Alluza, Hamid Hunaif Dhofi; Rosida, Nikma Alfi; Mayasari, Mayasari; Mustofa, Mustofa; Hartono, Adam; Aditya, Richi; Prastiwi, Firman; Meku, Fransiskus Xaverius; Sitio, Monika; Azmy, Abdullah; Santoso, Anita Surya; Nugroho, Radhitio Adi; Gersom, Camoya; Rabaan, Ali A.; Masyeni, Sri; Nainu, Firzan; Wagner, Abram L.; Dhama, Kuldeep; Harapan, Harapan
title: Predictors of COVID-19 severity: a systematic review and meta-analysis
date: 2020-09-09
journal: F1000Res
DOI: 10.12688/f1000research.26186.1
sha: 84a11b2c03cae7294efc560297c45dd00e2bcd3b
doc_id: 948577
cord_uid: jzfr2t3p

Background: The unpredictability of the progression of coronavirus disease 2019 (COVID-19) may be attributed to the low precision of the tools used to predict the prognosis of this disease. Objective: To identify the predictors associated with poor clinical outcomes in patients with COVID-19. Methods: Relevant articles from PubMed, Embase, Cochrane, and Web of Science were searched and extracted as of April 5, 2020. Data of interest were collected and evaluated for their compatibility for the meta-analysis. Cumulative calculations to determine the correlation and effect estimates were performed using the Z test. Results: In total, 19 papers recording 1,934 mild and 1,644 severe cases of COVID-19 were included. Based on the initial evaluation, 62 potential risk factors were identified for the meta-analysis. Several comorbidities, including chronic respiratory disease, cardiovascular disease, diabetes mellitus, and hypertension were observed more frequent among patients with severe COVID-19 than with the mild ones. Compared to the mild form, severe COVID-19 was associated with symptoms such as dyspnea, anorexia, fatigue, increased respiratory rate, and high systolic blood pressure. Lower levels of lymphocytes and hemoglobin; elevated levels of leukocytes, aspartate aminotransferase, alanine aminotransferase, blood creatinine, blood urea nitrogen, high-sensitivity troponin, creatine kinase, high-sensitivity C-reactive protein, interleukin 6, D-dimer, ferritin, lactate dehydrogenase, and procalcitonin; and a high erythrocyte sedimentation rate were also associated with severe COVID-19. Conclusion: More than 30 risk factors are associated with a higher risk of severe COVID-19. These may serve as useful baseline parameters in the development of prediction tools for COVID-19 prognosis.

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global crisis across health, economic, and educational dimensions 1, 2 . The disease has spread rapidly, can cause severe illness, and is characterized by a high mortality rate in certain groups. Mortality is particularly high in the absence of proven effective standard management measures 3 . One of the problems with the management of this disease is the absence of standardized methods for diagnosis and the inability to estimate prognosis based on clinical features. Certain reports have shown that poor prognostic prediction has correlated with high mortality among patients with COVID-19 4, 5 . Among patients with similar clinical characteristics and with similar treatment regiments, there may be a diversity in clinical outcomes 6 . Therefore, the development and use of an accurate predictor for COVID-19 prognosis will be beneficial for the clinical management of patients with COVID-19, and will help reduce the mortality rate. Successful implementation of such a prediction mechanism could have a large public health impact. Better understanding of clinical progression could also improve public health messaging, particularly as many individuals may consider COVID-19 to not be severe.

Prognostic tools for the prediction of COVID-19 severity in patients have been in development since January 2020. At least nine studies proposed the use of prognostic tools for the prediction of COVID-19 severity [7] [8] [9] [10] [11] [12] [13] [14] [15] . However, a recent systematic review and critical appraisal study evaluated the accuracy of these tools using prediction model risk of bias assessment tool (PROBAST) and reported a high risk of bias 16 . The establishment of a prediction model for the estimation of disease prognosis may help health workers segregate patients according to prediction status. However, the high risk of bias in these prediction tools might lead to inaccurate prediction of COVID-19 severity. A comprehensive study of the identification of risk factors that might play a significant role in determining the severity of patients with COVID-19 is necessary. We performed a systematic review and meta-analysis to assess the risk factors associated with poor clinical outcomes among patients with COVID-19. To the best of our knowledge, this is the first meta-analysis to assess the comprehensive risk factors that might affect the severity of COVID-19 in patients. The results of our study might serve as preliminary data for the compilation or improvement of the scoring system in the prediction of COVID-19 severity.

We performed a systematic review and meta-analysis to evaluate potential risk factors that might influence the severity of COVID-19. These risk factors include comorbidities, clinical manifestations, and laboratory findings. Accordingly, we searched the relevant studies from major scientific websites and databases to collect the data of interest, and determined the association and effect estimates by calculating the combined odds ratio (OR) and 95% confidence intervals (95% CI). The protocols for the systematic review and meta-analysis were similar to those used in previous studies 17-23 , as well as to those recommended by Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 24 .

Studies were included in this review if they met the following inclusion criteria: (1) assessed the clinical manifestations and laboratory findings of patients with mild to severe COVID-19;

(2) provided adequate data for the calculation of OR and 95% CI. Review articles, articles with non-standard data presentation, and duplicate publications were excluded.

Search strategy and data extraction Major scientific databases (PubMed, Embase, Cochrane, and Web of Science) were searched for articles as of April 5, 2020. A comprehensive initial search was performed to identify the potential predictors, and a final search was performed to identify the relevant papers that could be included in the meta-analysis. We used the keywords adapted from medical subject headings: ["COVID-19" or "Coronavirus disease-19" or "SARS-CoV-2"] and ["mild" or "severe" or "prognosis" or "clinical outcome"] and ["clinical manifestation" or "morbidity" or "laboratory findings"]. Only studies written in English were included. If a duplicate publication was found, the article with the larger sample size was included. We also searched for relevant studies from the reference lists in the articles. During data extraction, the following information of interest was extracted: (1) first author name;

(2) publication year; (3) sample size of mild and severe cases, (4) clinical manifestations, (5) morbidities, and (6) laboratory findings. Data extraction was performed by two independent investigators (JKF and MI) using a pilot form.

Before inclusion in the meta-analysis, the methodological quality of the articles was assessed using the New Castle-Ottawa scale (NOS). NOS scores range from 0 to 9 and consider three items: selection of patients (4 points), comparability of the groups (2 points), and ascertainment of exposure (3 points). Each study was interpreted to be of low quality (for scores ≤ 4), moderate quality (for scores between 5-6), or high quality (for scores ≥ 7) 25 . Articles with moderate to high quality were included in the analysis. The study assessment was conducted by two independent investigators (MI and YP) using a pilot form. The discrepancies between the findings of the two investigators were solved by consulting with another investigator (JKF).

The outcome measure of the study was the severity of COVID-19 (mild vs. severe). The risk factors or predictors included three major groups: comorbidities, clinical manifestations, and laboratory parameters. Comorbid factors such as chronic kidney disease, chronic liver disease, chronic respiratory disease, cerebrovascular accident, cardiovascular disease, diabetes mellitus, hypertension, and malignancy were compatible with the analysis. For clinical manifestations, fever, cough, dry cough, expectoration, sore throat, dyspnea, diarrhea, myalgia, nasal congestion, anorexia, abdominal pain, fatigue, dizziness, headache, fever, heart rate, respiratory rate, systolic blood pressure, and diastolic blood pressure were included in this study. Among laboratory characteristics, the presence of leukocytosis, leukocytopenia, anemia, lymphocytopenia; the levels or the counts of white blood cell (WBC), hemoglobin, neutrophil, lymphocyte, monocyte, platelet, activated partial thromboplastin time (aPTT), partial thromboplastin time (PTT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, serum creatinine, blood urea nitrogen (BUN), high-sensitivity (Hs)-troponin I, creatine kinase, high-sensitivity C-reactive protein (Hs-CRP), C-reactive protein (CRP) >8 mg/L, interleukin 6 (IL-6), glucose, D-dimer, serum ferritin, sodium, potassium, lactate dehydrogenase, and procalcitonin, CD4 and CD8; erythrocyte sedimentation rate (ESR); elevated IL-16; and elevated ESR were all included.

The significant risk factors that might govern the severity of COVID-19 were determined by the calculation of a pooled OR and 95% CI. The significance of the pooled ORs was determined using the Z test (p<0.05 was considered statistically significant). Prior to identification of the significant risk factors, data were evaluated for heterogeneity and potential publication bias. The heterogeneity among included studies was evaluated using the Q test. If heterogeneity existed (p<0.10), a random effect model was adopted; if not, a fixed effect model was adopted. Egger's test and a funnel plot were used to assess the reporting or publication bias (p<0.05 was considered statistically significant). Furthermore, we performed a moderator analysis to identify the independent predictors of poor clinical outcomes among patients with COVID-19. The data were analyzed using Review Manager version 5.3 (Revman Cochrane, London, UK). To prevent analytical errors, statistical analysis was performed by two authors (JKF and MI). The cumulative calculation was presented in a forest plot.

Our searches yielded 6,209 potentially relevant studies, of which 6,170 studies were excluded after assessment of the titles and abstracts. Subsequently, further review of the complete texts was performed for 39 potential studies. In the full text review, we excluded 20 studies because they were reviews articles (n = 9), inadequacy of data for the calculation of OR and 95% CI (n = 7), and poor quality (n = 4). Eventually, 19 papers were included in our meta-analysis 26-42 The paper selection process adopted in our study is summarized in Figure 1 , and the characteristics of studies included in our analysis are outlined in Table 1 .

We found that eight comorbidities, 19 clinical manifestations, and 35 laboratory parameters were available for the metaanalysis (Table 2 and Table 3 (Figure 2A-D) .

Among the clinical manifestations, dyspnea (OR: 3.28; 95% CI: 2.09, 5.15), anorexia (OR: 1.83; 95% CI: 1.00, 3.34), fatigue (OR: 2.00; 95% CI: 1.25, 3.20), and dizziness (OR: 2.67; 95% CI: 1.18, 6.01) were associated with severe COVID-19 ( Figure 3A -D). In addition, increased respiratory rate (OR: 2.85; 95% CI: 1.28, 6.33) and increased systolic blood pressure (OR: 1.84; 95% CI: 1.31, 2.60) were also associated with severe COVID-19 ( Figure 4A and B). Compared to productive cough, dry cough was associated with a lower risk of severe COVID-19 (OR: 0.66; 95% CI: 0.44, 0.97).

Among laboratory characteristics, severe COVID-19 was associated with elevated WBC count (OR: 4.92; 95% CI: 2.12, 11.31), increased neutrophil count (OR: 5.45; 95% CI: 2.04, 14.54), lymphocytopenia (OR: 3.19; 95% CI: 1.14, 7.07), and decreased hemoglobin levels (OR: 0.76; 95%CI: 0.58, 1.00) ( Figure 5A -D). Elevated levels of AST, ALT, and serum creatinine increased the risk for severe manifestations of COVID-19 (ORs 4.91, 3.23, and 2.14, respectively; Figure 

Heterogeneity was detected in the data of chronic kidney disease, cerebrovascular disease, cardiovascular disease, diabetes mellitus, hypertension, and malignancy among the comorbid factors analyzed. Therefore, we used the random effect model to analyze the data. The fixed effect model was used to analyze the data on chronic liver disease and chronic respiratory disease, as there was no evidence of heterogeneity. For clinical manifestations, the data on fever, cough, sore throat, dyspnea, diarrhea, anorexia, fatigue, temperature >38°C, respiratory rate, and diastolic blood pressure were analyzed using the random effect model while the rest of clinical manifestation data were analyzed using the fixed effect model.

Among laboratory parameters, evidence of heterogeneity was found in count of WBC, neutrophil, monocyte, lymphocyte, platelet, CD4, and CD8; the presence of lymphocytopenia and anemia; the levels of AST, ALT, total bilirubin, albumin, aPTT, PTT, serum creatinine, BUN, Hs-Troponin I, creatine kinase, IL-6, Hs-CRP, glucose, D-dimer, sodium, potassium, lactate dehydrogenase, and procalcitonin; elevated CRP; and ESR. Accordingly, the data were analyzed using the random effect model. The data for the remaining parameters were analyzed using the fixed effect model.

We used Egger's test to assess the potential publication bias. Our cumulative calculation revealed that reporting or publication bias (p<0.05) existed with respect to chronic liver disease, expectoration, myalgia, abdominal pain, heart rate, leukocytosis, elevated ESR, and elevated IL-6 levels.

Our data suggest that comorbidities, such as chronic respiratory disease, cardiovascular disease, diabetes, and hypertension, were associated with a higher risk of severe COVID-19, among which, hypertension was the strongest risk factor. These results are consistent with those of previous meta-analyses 43, 44 that indicated that chronic respiratory disease, cardiovascular disease, diabetes, and hypertension are significantly associated with higher COVID-19 mortality. Hypertension and diabetes are also associated with higher mortality among patients with dengue fever, West Nile virus infection, Zika virus infection, and yellow fever 45 . To date, no study has reported details of the primary mechanism underlying the association between severe COVID-19 and comorbid factors. However, immune responses might be the most crucial factor underlying this association. Patients with comorbidities such as cardiovascular disease, chronic respiratory disease, hypertension, and diabetes were observed to have a lower immunity status than healthy individuals 46-48 . Since COVID-19 primarily affects the respiratory tract 49 , patients with chronic respiratory diseases might be at a higher risk of contracting severe COVID-19. In addition, endothelial dysfunction might also play a pivotal role 50 .

COVID-19 is a novel disease, and the immune response of this disease is not completely understood. Our data suggest that elevated leukocyte and neutrophil levels and reduced lymphocyte levels are associated with severe COVID-19. In other viral infections, such as influenza, elevated leukocyte and neutrophil levels serve as important predictors of disease severity 51 . The role of leukocytes in the pathogenesis of COVID-19 is conflicting. In most cases, viral infections have been observed to cause leukopenia 52 . Furthermore, a study also reported that leukopenia was observed at a significantly higher frequency among COVID-19 patients than among non-COVID-19 patients 53 . However, in our present study, we did not compare COVID-19 and non-COVID-19 patients. The major factor that seemed to affect our findings was the occurrence of cytokine storm in patients. In COVID-19, there is an immune system overreaction, which results in a cytokine storm. In this condition, leukocytes might be over-activated, which might lead to the release of high levels of cytokines 54 . Consistent with our data, a study has confirmed that cytokine storm is significantly associated with severe COVID-19 55 . The theory underlying the role of neutrophils in COVID-19, as reported in our study, remains unclear. The speculations might be attributed to the involvement of neutrophil extracellular traps (NETs). While no study has assessed the precise role of NETs in COVID-19 pathogenesis, certain researchers speculate that SARS-CoV-2 might stimulate neutrophils to produce NETs, similar to several other viral pathogens 56 . Furthermore, this might lead to neutrophil infiltration in pulmonary capillaries, organ damage, and the development of acute respiratory distress syndrome 57 .

Low lymphocyte levels were observed in patients with severe COVID-19 compared with those with mild COVID-19. In the context of the immunological mechanism, our results might be contradictory. Lymphocyte subsets are known to play an important role in the action against bacterial, viral, fungal, and parasitic infections 58 ; therefore, the levels of circulating lymphocytes should increase. The immunological response in COVID-19 is unique and remains unclear. However, certain propositions might help describe our findings. First, coronaviruses infect human cells through ACE2 receptors 59 . Since ACE2 receptors are also expressed by lymphocytes 60 , the coronaviruses may enter lymphocytes and induce apoptosis. Second, the feedback mechanism between pro-inflammatory cytokines (such as IL-6) and lymphocytes might also explain our results.

A study revealed that elevation in the levels of pro-inflammatory cytokines correlated with reduction in the levels of lymphocytes 61 . Moreover, our findings also confirmed the significant elevation in the levels of IL-6. Third, ACE2 receptors are expressed by cells from various organs, including the thymus and spleen 62 . As coronaviruses infect human cells through the ACE2 receptors, the spleen and thymus might also be damaged in patients with COVID-19, which would lead to lower levels of lymphocyte production. Fourth, lymphocyte proliferation requires a balanced metabolism, and metabolic disorders such as hyperlactic acidemia have been reported to disturb lymphocyte proliferation 63 . Hyperlactic acidemia has been observed in patients with severe COVID-19 64 .

The studies included in this systematic review also suggest that the levels of D-dimer were significantly higher in patients with severe COVID-19. Coagulation in patients with COVID-19 has been a major concern, and the lack of reliable data and meta-analyses prevents a holistic comparison. Certain infectious diseases that cause abnormal coagulation have been associated with poor clinical outcomes 65 . The theory behind this mechanism is not understood clearly. It is widely known that ACE2 receptors are important for the infection of host cells by SARS-CoV-2, and ACE2 receptors are expressed in various cells in the human body, including endothelial cells 66 .

Consequently, a massive inflammatory reaction may occur in endothelial cells owing to SARS-CoV-2 infection 67 , which may lead to increased coagulation, disseminated intravascular coagulation 68 , and increased fibrin degradation 69 . High fibrin degradation leads to elevated levels of fibrinogen and D-dimer 70 , which might also explain the occurrence of venous thromboembolism in critical patients of COVID-19 71 . In addition, a study with a short follow-up period also reported the existence of a dynamic correlation between the D-dimer levels and the severity of COVID-19 72 . Furthermore, pulmonary embolism and deep vein thrombosis were also observed in patients with severe COVID-19 73, 74 , which suggests that D-dimer might play a prominent role in governing the severity of COVID-19 patients.

We also observed that inflammatory markers, including elevated levels of CRP, ESR, and IL-6, were found both in patients with severe and mild COVID-19, with a significant increase detected in patients with severe COVID-19. Other variables associated with adverse outcomes, such as ferritin, lactate dehydrogenase, and procalcitonin levels, were found to be elevated predominantly in patients with severe COVID-19. Our findings were consistent with those of a previous meta-analysis 75 , and indicated that high levels of CRP, lactate dehydrogenase, and ESR were associated with adverse outcomes in COVID-19. Another meta-analysis had also confirmed that elevated levels of IL-6 were observed in patients with COVID-19 who exhibited poor clinical outcomes 76 . Therefore, the levels of CRP, ESR, IL-6, ferritin, procalcitonin, and lactate dehydrogenase can serve as potential markers for the evaluation of COVID-19 prognosis.

The high mortality rate and treatment failure in patients with COVID-19 can be attributed to the fact that COVID-19 affects multiple organs, including the lung, heart, kidney, and liver 77 .

Our data suggest that elevated levels of urea and creatinine, and not chronic kidney disease, were associated with severe COVID-19, which indicates that acute inflammation might be caused by SARS-CoV-2 infection. Previous meta-analyses have also reported findings consistent with our results 78, 79 . Moreover, anatomical studies have reported significant renal inflammation in patients with severe COVID-19 75, 80, 81 . There might be two mechanisms by which SARS-CoV-2 induces renal inflammation. First, SARS-CoV-2 might directly infect renal tubular epithelial cells and podocytes through ACE2 receptors, which facilitates the targeted infection of certain cells by the virus. Consequently, acute tubular necrosis, podocytopathy, microangiopathy, and collapsing glomerulopathy might occur owing to the massive inflammation in renal tubular epithelial cells and podocytes 82, 83 . Second, the binding between SARS-CoV-2 and ACE2 receptors might activate angiotensin II and induce cytokine production, which may lead to hypercoagulopathy and microangiopathy, and eventually cause renal hypoxia 84, 85 .

Conversely, with respect to liver function, we observed that the levels of liver enzymes were higher in patients with severe COVID-19. Previous studies in this context have elucidated that ACE2 receptors are highly expressed in bile duct cells; therefore, infection of these cells by coronaviruses might lead to abnormalities in the levels of liver enzymes 86 . However, a recent anatomical study on liver biopsy specimens from patients with severe COVID-19 revealed that moderate microvascular steatosis and mild lobular and portal activities were observed 87 . These data suggest that it cannot be determined clearly whether the elevated levels of liver enzymes in patients with severe COVID-19 are caused by direct infection or by drug-induced liver injury. Therefore, further studies are required to elucidate the precise mechanism underlying the elevation of liver enzymes levels in patients with severe COVID-19. 75 . In our study, we included all comorbidities, clinical manifestations, and laboratory characteristics. Additionally, compared to previous studies, this study has a larger sample size; the data on 1,934 patients with mild and 1,644 patients with severe COVID-19 treated across 19 hospitals were retrieved. However, this study also has certain limitations. Certain crucial factors that might play an important role in the pathogenesis of COVID-19, including secondary infection, treatment, and immunological status were not controlled for. Our current findings should be interpreted with caution because the majority of studies included were cross-sectional, and the samples corresponding to the data analyzed originated only in China. Longitudinal studies may reveal more long-term impacts of SARS-CoV-2 infection 92 .

COVID-19 is an emergent infectious disease, and the major problem associated with it is the unknown pattern of disease development. We identified 34 factors that are associated with severe COVID-19. This might improve our understanding of COVID-19 progression and provide baseline data to compile or improve the prediction models for the estimation of COVID-19 prognosis.

Underlying data All data underlying the results are available as part of the article and no additional source data are required. 

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

Prevalence and fatality rates of COVID-19: What are the reasons for the wide variations worldwide

Predicting the mortality due to Covid-19 by the next month for Italy, Iran and South Korea; a simulation study

PubMed Abstract | Publisher Full Text | Free Full Text 6. Siordia JA: Epidemiology and clinical features of COVID-19: A review of current literature

Predicting COVID-19 malignant progression with AI techniques

A tool to early predict severe 2019-novel coronavirus pneumonia (COVID-19):a multicenter study using the risk nomogram in Wuhan and Guangdong, China

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Neutrophil extracellular traps

Inhibitory effect of tumor cell-derived lactic acid on human T cells

A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm)

Infection and inflammation and the coagulation system

Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis

Endothelial cell infection and endotheliitis in COVID-19

COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)

PubMed Abstract | Publisher Full Text | Free Full Text

COVID-19 update: Covid-19-associated coagulopathy

PubMed Abstract | Publisher Full Text | Free Full Text

Fibrin D-dimer in thrombogenic disorders

The need to manage the risk of thromboembolism in COVID-19 patients

D-dimer in patients infected with COVID-19 and suspected pulmonary embolism

COVID-19 complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure

Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Elevated interleukin-6 and severe COVID-19: A meta-analysis

COVID-19 and Multiorgan Response

Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis

Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis

Kidney biopsy findings in a critically ill COVID-19 patient with dialysis-dependent acute kidney injury: a case against "SARS-CoV-2 nephropathy

COVID-19): A literature review

Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology

PubMed Abstract | Publisher Full Text | Free Full Text

COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity

Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19

PubMed Abstract | Publisher Full Text | Free Full Text

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. Publisher Full Text

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

The Clinical Manifestations and Chest Computed Tomography Findings of Coronavirus Disease 2019 (COVID-19) Patients in China: A Proportion Meta-Analysis

Laboratory findings of COVID-19: a systematic review and meta-analysis

Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis

PubMed Abstract | Publisher Full Text | Free Full Text

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

Predictors of COVID-19 severity: a systematic review and meta-analysis". figshare

Publisher Full Text Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Yes

The authors highlight the need for a scoring system for the prediction of severity. There is another reason why it is important to identify risk factors for severe disease: to guide prioritization of high risk target populations for vaccination

Competing Interests: No competing interests were disclosed.Reviewer Expertise: COVID-19, Zika and dengue I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.Reviewer Report 21 September 2020 https://doi.org/10.5256/f1000research.28897.r71054 © 2020 Arab-Zozani M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In this meta-analysis, you investigated the predictors of COVID-19 severity through the literature. You considered a topic of interest and provided a well-written manuscript. However, there are some things that will improve your reporting.Abstract, method section, please insert detail about critical/quality appraisal of the included studies.○ Abstract, method section, line 1, please remove " and extracted" from the text. It maybe causes a misunderstanding between this step and the data extraction step. 

Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes

Are the conclusions drawn adequately supported by the results presented in the review? YesCompeting Interests: No competing interests were disclosed.Reviewer Expertise: Systematic review and meta-analysis in health and medical intervention I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.The benefits of publishing with F1000Research:Your article is published within days, with no editorial bias • You can publish traditional articles, null/negative results, case reports, data notes and more • The peer review process is transparent and collaborative • Your article is indexed in PubMed after passing peer review • Dedicated customer support at every stage • For pre-submission enquiries, contact research@f1000.com